Acticor Biotech selects GPEx® Technology to develop ACT-017
Acticor Biotech today announced that it selected Catalent’s proprietary GPEx® technology for the development of its Fab candidate, ACT-017, targeting the platelet glycoprotein VI (GPVI).
Catalent & Cerenis Therapeutics Announce Phase III Trial of CER-001
Catalent Pharma Solutions today announced that Cerenis Therapeutics has advanced its leading clinical candidate, CER-001, into Phase III clinical studies across Europe and North America.
Catalent Biologics Collaborates with Roche on SMARTag® Technology
Catalent today announced, through its wholly-owned subsidiary, Redwood Bioscience, Inc., a research collaboration with Roche to develop next-generation molecules coupling different therapeutic modalities using Catalent’s proprietary SMARTag® technology.